Canada Clinical Trials Group Contribution to NCI Program

该应用程序的最终目标是增强我们可靠而高效地回答癌症治疗中的关键问题的能力。由于随机临床试验为癌症治疗的有效性提供了最好的证据，国家癌症研究所通过癌症治疗评估计划的临床研究分支为临床试验合作小组计划提供资金。在过去的几年里，临床试验方案已经做出了实质性的改变，以促进研究的更快发展和完成 这解决了癌症治疗中的重要问题。这些变化对包括加拿大在内的整个北美地区的合作临床试验的开展产生了重大影响。 加拿大国家癌症研究所是一个由加拿大癌症协会捐款资助的机构，它支持一个功能类似于美国小组的国家临床试验小组(NCIC CTG)。自1988年以来，NCIC CTG一直由美国国立卫生研究院资助，以支持该小组对涉及两个或更多小组之间的合作努力的试验的贡献--“小组间”试验。这项申请的目的是更新和扩大这笔资金，使NCIC CTG能够积极参与临床试验的“新国家系统”。这项建议的具体目的与我们最初申请时相同；即：1.贡献患者 为NCI赞助的组间试验提供招募、数据管理资源和高质量的数据；2.为NCI组间试验的开发、设计和实施提供科学投入；3.为NCI组间试验提供领导和协调资源。然而，由于过去五年该奖项支持的工作以及临床试验系统的变化，此次申请的重点是我们作为北美大型研究的领导者的角色。

The ultimate goal of this application is to enhance our ability to answer, reliably and efficiently, critical questions in the treatment of cancer. Because randomized clinical trials provide the best evidence of the effectiveness of cancer treatments, the National Cancer Institute funds a Clinical Trials Cooperative Group Program through the Clinical Investigations Branch of the Cancer Therapy Evaluation Program. In the past few years, substantial changes have been made to the Clinical Trials Program in order to promote the more rapid development and completion of studies that address important issues in cancer treatment. These changes have had a major impact on the conduct of cooperative clinical trials throughout North America, including Canada. The National Cancer Institute of Canada, an agency funded by donations to the Canadian Cancer Society, supports a national clinical trials group (NCIC CTG) that functions similarly to US groups. Since 1988, the NCIC CTG has been funded by NIH to support the Group's contribution to trials that involve a collaborative effort between two or more groups - "intergroup" trials. The purpose of this application is to renew and expand that funding in a manner that will allow the NCIC CTG to participate actively in the "New National System" of clinical trials. The specific aims of the proposal are the same as they were in our initial application; namely: 1. To contribute patient enrollment, data management resources, and high quality data to intergroup trials sponsored by NCI; 2. To provide scientific input into the development, design and conduct of NCI intergroup trials; and 3. To provide leadership and coordination resources for some NCI intergroup trials. However, because of the work supported by this award in the past five years and the changes in the clinical trials system, the emphasis of this application is on our role a leader of large North American studies.